Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$12.32 USD

12.32
6,405,600

-0.31 (-2.45%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $12.30 -0.02 (-0.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Emergent (EBS) Begins Dosing in Study on Influenza Vaccine

by Zacks Equity Research

Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.

Moderna's (MRNA) Flu Vaccine Data Fails to Impress Investors

by Zacks Equity Research

Moderna's (MRNA) early-stage flu vaccine data seems promising but it fails to meet investors' expectations.

Kinjel Shah headshot

Vaccine Stocks Down as Omicron May Not Be Too Severe

by Kinjel Shah

Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.

Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab

by Zacks Equity Research

Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.

Moderna (MRNA) Rallies on Booster Hopes Amid Omicron Concerns

by Zacks Equity Research

Demand for Moderna's (MRNA) COVID-19 vaccine booster dose might increase if the Omicron variant causes a rise in infection rates.

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and Novavax

Mark Vickery headshot

Nice Relief Rally on Biotech Assurances, Home Sales Data

by Mark Vickery

The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.

Mark Vickery headshot

Nice Relief Rally on Biotech Assurances, Home Sales Data

by Mark Vickery

The Dow crossed back north of 35K, +236 points or +0.68%, while the S&P 500 put up its best trading day in six weeks.

Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?

by Zacks Equity Research

Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.

Novavax (NVAX) Stock Up YTD on COVID-19 Vaccine Potential

by Zacks Equity Research

Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.

Are Options Traders Betting on a Big Move in Novavax (NVAX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Novavax (NVAX) COVID Jab Gets Philippines Nod, Under Review in EU

by Zacks Equity Research

Novavax's (NVAX) secures approval for its COVID vaccine in the Philippines. The EMA begins reviewing the company's regulatory submission for its COVID vaccine. Evidently, the stock gains.

Novavax's (NVAX) Q3 Loss Widens, Revenues Lag Estimates

by Zacks Equity Research

Novavax (NVAX) reports wider-than-expected loss for the third quarter of 2021 while revenues miss estimates. Shares down.

Novavax (NVAX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -6.68% and -41.71%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More

by Zacks Equity Research

Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.

Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Novavax's (NVAX) upcoming third-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed at $148.83 in the latest trading session, marking a -1.19% move from the prior day.

Earnings Preview: Novavax (NVAX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed the most recent trading day at $138.79, moving +1.41% from the previous trading session.

Novavax (NVAX) Down on COVID Jab-Manufacturing Problem Reports

by Zacks Equity Research

Novavax's (NVAX) shares fall on reports of the company's manufacturing problems related to its COVID-19 vaccine candidate.

Novavax (NVAX) Lags in COVID Vaccine Race: Will It Gather Pace?

by Zacks Equity Research

Novavax (NVAX) is progressing well with its COVID-19 and flu vaccines. However, it is lagging in the COVID-19 vaccine space. Let us see how the company is likely to perform going forward.

Novavax (NVAX) Concentrates on COVID-19 Vaccine Development

by Zacks Equity Research

While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.

Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EUSA

3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data

by Zacks Equity Research

Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.

Kinjel Shah headshot

Vaccine Stocks Down Following Merck's COVID-19 Pill Success

by Kinjel Shah

Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19